Multiple Sclerosis Trial Completed Patient Visits
The INFORM-MS study examined an intranasal treatment for patients with non-active secondary progressive disease.
Updated on Sept. 21, 2026 in Alzheimer’s
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes during the drug development process?
Tiziana Life Sciences has concluded patient visits for its Phase 2a clinical trial evaluating the drug foralumab. The study aimed to assess the therapy for patients with non-active secondary progressive multiple sclerosis.
Why it matters
Researchers are investigating whether this treatment can safely address neuroinflammation in a form of multiple sclerosis that currently has limited therapeutic options. The findings will help determine if this approach merits further development in larger clinical studies.
This Phase 2a trial enrolled 48 patients across U.S. sites to evaluate the safety and efficacy of intranasal foralumab over 12 weeks. Researchers are measuring changes in microglial activation via PET imaging, with final results not yet available.
The players
Tiziana Life Sciences
A biotechnology company focused on developing immunomodulatory therapies for autoimmune and inflammatory diseases including multiple sclerosis.
The details
Foralumab is a fully human anti-CD3 monoclonal antibody designed to modulate immune system activity. Administered intranasally, the drug seeks to reduce neuroinflammation associated with disease progression. The trial uses PET imaging to quantify microglial activation in the brain, alongside standard clinical metrics like the Expanded Disability Status Scale and the Modified Fatigue Impact Scale.
Timeline
September 21, 2026: Tiziana Life Sciences announced the completion of the final patient visit.
This week: The company expects to lock the trial database.
October 2026: The company expects to announce 12-week topline trial data.
Health Landscape
This study follows a pattern set by early-phase neuro-immunology research targeting microglial activation in secondary progressive MS. It represents a shift toward investigating localized, immune-modulating treatments for progressive conditions.
Patients with multiple sclerosis should note that this remains an investigational study and is not yet a clinical treatment option. Discuss current approved therapies and ongoing clinical trial eligibility with your neurologist.
The takeaway
This trial marks a step toward evaluating new ways to modulate immune activity in non-active secondary progressive multiple sclerosis. Patients interested in emerging research should follow future clinical trial announcements and discuss their progression status with a neurologist.
What happens next
Tiziana Life Sciences expects to lock the trial database this week and announce topline results in October 2026.
Further reading
Find more on the latest research and disease management resources in the Alzheimer’s section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes during the drug development process?
